Literature DB >> 10942658

The current use of botulinum toxin.

N Mahant1, P D Clouston, I T Lorentz.   

Abstract

Botulinum toxin is the most potent neurotoxin known, and has been in clinical use since the late 1970s. The toxin inhibits the release of acetylcholine from nerve terminals by inhibiting transport of the synaptic vesicles, thus causing functional denervation lasting up to 6 months. Our understanding of the mechanism of action of the toxin and the spectrum of diseases treatable with this agent continues to increase. Efficacy has been demonstrated in hemifacial spasm, dystonia, spasticity, hyperhidrosis and other conditions. Alternative serotypes are used in some centres, generally after the development of immunoresistance to the standard toxin (serotype A), and are likely to be in routine use in the near future. This paper reviews the history, pharmacology and current uses of botulinum toxin. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942658     DOI: 10.1054/jocn.2000.0684

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  15 in total

Review 1.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

2.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

3.  Ganglion impar block with botulinum toxin type a for chronic perineal pain -a case report-.

Authors:  Su Jin Lim; Hue Jung Park; Sang Hoon Lee; Dong Eon Moon
Journal:  Korean J Pain       Date:  2010-03-10

4.  Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells.

Authors:  Min Dong; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-01       Impact factor: 11.205

5.  Modification of blood vessel diameter following perivascular application of botulinum toxin-A.

Authors:  Peter B Arnold; Chris A Campbell; George Rodeheaver; Wyndell Merritt; Raymond F Morgan; David B Drake
Journal:  Hand (N Y)       Date:  2009-02-05

Review 6.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

7.  Apoptotic action of botulinum toxin on masseter muscle in rats: early and late changes in the expression of molecular markers.

Authors:  Young-Min Moon; Min-Keun Kim; Seong-Gon Kim; Tae-Woo Kim
Journal:  Springerplus       Date:  2016-07-07

8.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.

Authors:  Min Dong; David A Richards; Michael C Goodnough; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  J Cell Biol       Date:  2003-09-22       Impact factor: 10.539

9.  Substrate-based inhibitors exhibiting excellent protective and therapeutic effects against Botulinum Neurotoxin A intoxication.

Authors:  Jiubiao Guo; Jinglin Wang; Shan Gao; Bin Ji; Edward Waichi Chan; Sheng Chen
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

10.  Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.

Authors:  Christine Rasetti-Escargueil; Arnaud Avril; Siham Chahboun; Rob Tierney; Nicola Bak; Sebastian Miethe; Christelle Mazuet; Michel R Popoff; Philippe Thullier; Michael Hust; Thibaut Pelat; Dorothea Sesardic
Journal:  MAbs       Date:  2015-09-18       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.